CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomasJoseph Flores‐Toro, Jeffrey K. Harrison, James J. Campbell et al.|Proceedings of the National Academy of Sciences|2019Cited by 330
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor modelJ. Bryan Iorgulescu, David A. Reardon, Neil Ruthen et al.|Frontiers in Immunology|2023Cited by 23